Royal Bank of Canada set a $66.00 price target on Integra Lifesciences (NASDAQ:IART) in a research report sent to investors on Friday morning, TipRanks reports. The firm currently has a hold rating on the life sciences company’s stock.

Several other equities research analysts also recently issued reports on IART. BidaskClub downgraded Woodward, Inc.Common Stock from a strong-buy rating to a buy rating in a report on Saturday. ValuEngine upgraded United States Steel from a strong sell rating to a sell rating in a report on Wednesday, July 24th. Wells Fargo & Co reiterated a buy rating and issued a $125.00 price objective on shares of Tractor Supply in a report on Thursday. Oppenheimer boosted their price objective on Facebook from $225.00 to $230.00 and gave the company an outperform rating in a report on Thursday. Finally, JMP Securities boosted their price objective on Facebook from $220.00 to $250.00 and gave the company an outperform rating in a report on Thursday. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and six have assigned a buy rating to the stock. The stock currently has a consensus rating of Hold and an average price target of $61.92.

Shares of IART stock traded down $0.40 on Friday, hitting $62.87. The stock had a trading volume of 31,399 shares, compared to its average volume of 405,574. The company has a debt-to-equity ratio of 0.99, a current ratio of 2.76 and a quick ratio of 1.82. The firm has a market capitalization of $5.41 billion, a price-to-earnings ratio of 25.98, a P/E/G ratio of 1.98 and a beta of 1.07. Integra Lifesciences has a 1 year low of $42.14 and a 1 year high of $66.41. The firm has a 50 day moving average of $53.88.

Integra Lifesciences (NASDAQ:IART) last posted its quarterly earnings data on Wednesday, July 24th. The life sciences company reported $0.73 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.65 by $0.08. The firm had revenue of $383.60 million for the quarter, compared to the consensus estimate of $373.29 million. Integra Lifesciences had a return on equity of 16.30% and a net margin of 6.76%. The company’s quarterly revenue was up 4.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.60 EPS. Equities analysts forecast that Integra Lifesciences will post 2.73 earnings per share for the current fiscal year.

In related news, VP Daniel L. Reuvers sold 5,000 shares of the business’s stock in a transaction on Wednesday, July 24th. The stock was sold at an average price of $60.00, for a total transaction of $300,000.00. Following the completion of the transaction, the vice president now directly owns 35,392 shares of the company’s stock, valued at approximately $2,123,520. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Christian S. Schade sold 15,658 shares of the business’s stock in a transaction on Friday, May 10th. The stock was sold at an average price of $51.56, for a total value of $807,326.48. The disclosure for this sale can be found here. Insiders have sold a total of 27,808 shares of company stock valued at $1,509,326 over the last three months. 4.50% of the stock is currently owned by insiders.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Steward Partners Investment Advisory LLC acquired a new position in Integra Lifesciences during the 2nd quarter worth $26,000. Quadrant Capital Group LLC boosted its position in shares of Integra Lifesciences by 223.0% during the 1st quarter. Quadrant Capital Group LLC now owns 646 shares of the life sciences company’s stock worth $34,000 after acquiring an additional 446 shares in the last quarter. BNP Paribas Arbitrage SA boosted its position in shares of Integra Lifesciences by 120.1% during the 1st quarter. BNP Paribas Arbitrage SA now owns 2,320 shares of the life sciences company’s stock worth $129,000 after acquiring an additional 1,266 shares in the last quarter. World Asset Management Inc acquired a new position in shares of Integra Lifesciences during the 1st quarter worth about $217,000. Finally, Stanley Laman Group Ltd. acquired a new position in shares of Integra Lifesciences during the 1st quarter worth about $223,000. 82.18% of the stock is owned by hedge funds and other institutional investors.

About Integra Lifesciences

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.

Further Reading: Asset Allocation Models, Which is Right For You?

Analyst Recommendations for Integra Lifesciences (NASDAQ:IART)

Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.